Parinati Kharel

Parinati Kharel has a strong background in scientific research, with experience in various roles and companies. Parinati is currently working as a Senior Scientist I at Nitto BioPharma since May 2021. Prior to that, they worked at Pfizer as a Scientist, Viral Vaccines from December 2019 to April 2021. Before joining Pfizer, Parinati was a Research Associate at Evotec from June 2018 to December 2019.

Parinati gained valuable experience at Weill Cornell Medicine, where they worked as a Research Specialist from September 2015 to May 2018. During their time there, they provided support in molecular and cell biology, performing tasks such as designing and cloning shRNAs, expressing and purifying proteins, and genotyping mice. Parinati also conducted experiments to study the effect of Munc18-1 disease-linked mutations and identified chemical chaperones that can rescue Munc18-1 mutant protein levels.

Prior to their role at Weill Cornell Medicine, Parinati worked as an Associate Researcher II at the Icahn School of Medicine at Mount Sinai from September 2013 to September 2015. Parinati started their research career as a Graduate Research Assistant at Southern Illinois University, Carbondale from August 2010 to May 2013.

Overall, Parinati Kharel has amassed extensive experience in scientific research, particularly in the fields of viral vaccines and molecular and cell biology.

Parinati Kharel pursued a Bachelor's degree at The University of Texas at Arlington. Parinati'smajor was Microbiology, with a minor in Chemistry. After completing their undergraduate studies, they attended Southern Illinois University, Carbondale, where they obtained a Master of Science (M.Sc.) degree in Biochemistry and Molecular Biology. In addition to their formal education, Parinati Kharel also earned several certifications, including Drug Discovery from Coursera in December 2017, HTML, CSS, and Javascript for Web Developers from Coursera in January 2017, and Business Metrics for Data-Driven Companies from Coursera Course Certificates in November 2016.